Abstract
IntroductionPhysical health conditions are the leading causes of death in people living with severe mental illness. In particular, the risk of metabolic syndrome; the constellation of abnormalities in weight, blood pressure, blood glucose and lipid levels, is high in this cohort. It has been recognised that commonly prescribed pharmacological agents for mental illness can further amplify the risk of developing metabolic syndrome; therefore, monitoring guidelines are in place for consumers prescribed antipsychotics. However, there is a disconnect between recommended guidelines and current practice. Our study aims to investigate: (1) the feasibility of a community pharmacist-led physical health monitoring for metabolic parameters in consumers with mental illness currently taking second generation antipsychotics and (2) the potential outcomes of the intervention (eg, rates and outcome of referrals to general practitioners, relationship between the pharmacist’s lifestyle counselling advice and change in metabolic parameters).Methods and analysisWe propose a longitudinal metabolic monitoring study led by community pharmacists with one-to-one consultations between trained pharmacists and participants at set intervals over a 12-month period. Our primary outcome is to determine the feasibility of the pharmacist-led intervention. The secondary outcome is to explore the overall health outcomes of consumers enrolled in the intervention. This is a mixed-methods study including both quantitative and qualitative outcomes. Qualitative data will be analysed via the process of data immersion, coding and identification of themes. Quantitative outcomes will be analysed using IBM Statistics SPSS software. Univariate descriptive, regression analysis and dependent t-tests will be performed. Statistical significance will be at α 0.05.Ethics and disseminationOur study has been approved by the institutional Human Research Ethics Committee (Protocol no: 203433). Findings will be made publicly available in peer-reviewed articles, conference presentations to health professionals, as well as other stakeholders. Protocol V.2.1, August 2021.Trial registration numberACTRN12621001435875.
Funder
University of South Australia
Reference49 articles.
1. World Health Organization . Schizophrenia, 2020. Available: https://www.who.int/news-room/fact-sheets/detail/schizophrenia [Accessed 13 Jul 2019].
2. World Health Organization . Premature death among people with severe mental disorders, 2013. Available: https://www.who.int/mental_health/management/info_sheet.pdf [Accessed 13 Jul 2020].
3. Understanding Excess Mortality in Persons With Mental Illness
4. Metabolic Syndrome and Risk of Incident Cardiovascular Events and Death
5. Antipsychotic-Induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia;Casey;J Clin Psychiatry,2004
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献